Welcome to the international HTA database

Showing [16534 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2016	Agency for Healthcare Research and Quality (AHRQ)	Renal denervation in the Medicare Population
2016	National Institute for Health and Care Excellence (NICE)	Apremilast for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 419
2016	NIHR Health Technology Assessment programme	Clinical effectiveness and cost-effectiveness of physiotherapy and occupational therapy versus no therapy in mild to moderate Parkinson s disease: a large pragmatic randomised controlled trial (PD REHAB)
2016	NIHR Health Technology Assessment programme	Tackling obesity in areas of high social deprivation: clinical effectiveness and cost-effectiveness of a task-based weight management group programme a randomised controlled trial and economic evaluation
2016	NIHR Health Technology Assessment programme	Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation
2016	NIHR Health Technology Assessment programme	Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high incidence of tuberculosis: systematic review and economic evaluation
2016	National Institute for Health and Care Excellence (NICE)	Ticagrelor for preventing atherothrombotic events after myocardial infarction. NICE technology appraisal guidance 420
2016	NIHR Health Technology Assessment programme	The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study
2016	NIHR Health Technology Assessment programme	The identification and treatment of women with hyperglycaemia in pregnancy: an analysis of individual participant data, systematic reviews, meta-analyses and an economic evaluation
2016	National Institute for Health and Care Excellence (NICE)	Everolimus with exemestane for treating advanced breast cancer after endocrine therapy. NICE technology appraisal guidance 421
2016	NIHR Health Technology Assessment programme	A multicentre, randomised controlled trial comparing the clinical effectiveness and cost-effectiveness of early nutritional support via the parenteral versus the enteral route in critically ill patients (CALORIES)
2016	NIHR Health Technology Assessment programme	Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis
2016	National Institute for Health and Care Excellence (NICE)	Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 422
2016	NIHR Health Technology Assessment programme	Orthotic management of instability of the knee related to neuromuscular and central nervous system disorders: systematic review, qualitative study, survey and costing analysis
2016	Health Quality Ontario (HQO)	Levonorgestrel-releasing intrauterine sSystem (52 mg) for idiopathic heavy menstrual bleeding: a health technology assessment
2016	National Institute for Health and Care Excellence (NICE)	Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens. NICE technology appraisal guidance 423
2016	NIHR Health Technology Assessment programme	The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysis
2016	NIHR Public Health Research (PHR) programme	Implications for public health research of models and theories of disability: a scoping study and evidence synthesis
2016	Health Quality Ontario (HQO)	Transcatheter aortic valve implantation for treatment of aortic valve stenosis: a health technology assessment
2016	National Institute for Health and Care Excellence (NICE)	Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer. NICE technology appraisal guidance 424
2016	NIHR Health Technology Assessment programme	A randomised controlled trial to measure the effects and costs of a dental caries prevention regime for young children attending primary care dental services: the Northern Ireland Caries Prevention In Practice (NIC-PIP) trial
2016	NIHR Health Technology Assessment programme	Social Stories to alleviate challenging behaviour and social difficulties exhibited by children with autism spectrum disorder in mainstream schools: design of a manualised training toolkit and feasibility study for a cluster randomised controlled trial with nested qualitative and cost-effectiveness components
2016	NIHR Health Technology Assessment programme	Bladder ultrasonography for diagnosing detrusor overactivity: test accuracy study and economic evaluation
2016	NIHR Health Services and Delivery Research programme	Do-not-attempt-cardiopulmonary-resuscitation decisions: an evidence synthesis
2016	NIHR Health Services and Delivery Research programme	The Prevalence of Visual Impairment in People with Dementia (the PrOVIDe study): a cross-sectional study of people aged 60-89 years with dementia and qualitative exploration of individual, carer and professional perspectives
2016	Health Quality Ontario (HQO)	Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: a health technology assessment
2016	National Institute for Health and Care Excellence (NICE)	Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia. NICE technology appraisal guidance 425
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Everolimus (Afinitor) for diffuse large B-cell lymphoma – maintenance therapy
2016	NIHR Health Services and Delivery Research programme	Determining the optimal model for role substitution in NHS dental services in the UK: a mixed-methods study
2016	Health Quality Ontario (HQO)	Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: OHTAC recommendation
2016	National Institute for Health and Care Excellence (NICE)	Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia. NICE technology appraisal guidance 426
2016	NIHR Health Technology Assessment programme	Clinical effectiveness and cost-effectiveness of body psychotherapy in the treatment of negative symptoms of schizophrenia: a multicentre randomised controlled trial
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Dabrafenib (Tafinlar) and trametinib (Mekinist) combination therapy for advanced BRAF mutated non-small cell lung cancer
2016	Adelaide Health Technology Assessment (AHTA)	Microwave tissue ablation for primary and secondary liver cancer
2016	Health Quality Ontario (HQO)	Levonorgestrel-releasing intrauterine system (52 mg) for idiopathic heavy menstrual bleeding: OHTAC Recommendation
2016	NIHR Horizon Scanning Centre (NIHR HSC)	ADI-PEG 20 for hepatocellular carcinoma – second line
2016	Health Quality Ontario (HQO)	Transcatheter aortic valve implantation for treatment of aortic valve stenosis: OHTAC recommendation
2016	NIHR Health Technology Assessment programme	An observational study of Donor Ex Vivo Lung Perfusion in UK lung transplantation: DEVELOP-UK
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Heartcel for heart failure in patients at risk of incomplete revascularisation following coronary artery bypass graft
2016	NIHR Public Health Research (PHR) programme	IMPRoving Outcomes for children exposed to domestic ViolencE (IMPROVE): an evidence synthesis
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Furosemide sc2Wear micro-pump patch for oedema in heart failure
2016	NIHR Health Services and Delivery Research programme	Getting the most out of knowledge and innovation transfer agents in health care: a qualitative study
2016	NIHR Health Technology Assessment programme	A cluster randomised trial of strategies to increase cervical screening uptake at first invitation (STRATEGIC)
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Pertuzumab (Perjeta) with chemotherapy and trastuzumab for HER2-positive early breast cancer – adjuvant therapy
2016	NIHR Health Services and Delivery Research programme	Location of care for people with serious mental illness (LOCAPE): implications for service use and costs using a mixed-methods approach
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Remestemcel-L for graft vs host disease in paediatric patients – second line
2015	Institute for Clinical Evaluative Sciences (ICES)	The mental health of children and youth in Ontario: a baseline scorecard
2015	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	Once more a test title
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Pembrolizumab (Keytruda) for PD-L1 strong-positive metastatic non-small cell lung cancer – first line
2015	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Hysteroscopy for abnormal uterine bleeding: review of clinical evidence and guidelines
2015	Institute for Clinical Evaluative Sciences (ICES)	Atlas of childhood cancer in Ontario 1985-2004
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Glycerol phenylbutyrate (Ravicti) for urea cycle disorders (hyperammonaemia)
2015	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	And another test title
2015	NIHR Horizon Scanning Centre (NIHR HSC)	GSK2696273 for severe combined immunodeficiency due to adenosine deaminase deficiency
2015	Canadian Agency for Drugs and Technologies in Health (CADTH)	Holkira (ombitasvir/paritaprevir/ ritonavir with dasabuvir) and Harvoni (ledipasvir/sofosbuvir) for chronic hepatitis C: a review of the clinical evidence
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Lopixibat for progressive familial intrahepatic cholestasis in paediatric patients
2015	Canadian Agency for Drugs and Technologies in Health (CADTH)	Vitamin D testing in the general population: a review of the clinical and cost-effectiveness and guidelines
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Masitinib for Crohn's disease, in patients intolerant or with an unsatisfactory response to immunosuppressive drugs and/or TNF-inhibitors
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Masitinib for primary and relapse-free secondary progressive multiple sclerosis – first line
2015	Canadian Agency for Drugs and Technologies in Health (CADTH)	Telehealth services for the treatment of psychiatric issues: clinical effectiveness, safety, and guidelines
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Masitinib for rheumatoid arthritis – second and subsequent line
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Sirukumab for rheumatoid arthritis
2015	NIHR Health Technology Assessment programme	A feasibility randomised controlled trial of a motivational interviewing-based intervention for weight loss maintenance in adults
2015	Canadian Agency for Drugs and Technologies in Health (CADTH)	Electroconvulsive therapy performed outside of surgical suites: a review of the clinical effectiveness, safety, and guidelines
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Tadalafil (Cialis) for Duchenne muscular dystrophy
2015	Technology Assessment at SickKids (TASK)	Thiopurine S-methyltransferase testing for averting drug toxicity in patients receiving thiopurines: A systematic review and quality appraisal
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Ataluren (Translarna) for CFTR class I nonsense mutation mediated cystic fibrosis
2015	NIHR Health Services and Delivery Research programme	Secondary analysis and literature review of community rehabilitation and intermediate care: an information resource
2015	Technology Assessment at SickKids (TASK)	Thiopurine S-methyltransferase testing for averting drug toxicity in patients receiving thiopurines: A meta-analysis of diagnostic test accuracy
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Benralizumab for uncontrolled asthma – second line
2015	Agency for Healthcare Research and Quality (AHRQ)	Emerging approaches to diagnosis and treatment of non–muscle-invasive bladder cancer
2015	Canadian Agency for Drugs and Technologies in Health (CADTH)	Immediate osseointegrated implants for cancer patients: a review of clinical and cost-effectiveness
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Abiraterone (Zytiga) for hormone-naïve metastatic prostate cancer – first line
2015	Health Council of the Netherlands Gezondheidsraad (GR)	Next generation sequencing in diagnosis
2015	HAYES, Inc.	Continuous glucose monitoring systems
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Bevacizumab (Avastin) with lomustine for glioblastoma – second line
2015	Health Council of the Netherlands Gezondheidsraad (GR)	Checking checked: appropriate use of health checks
2015	HAYES, Inc.	Digital breast tomosynthesis for breast cancer diagnosis and screening
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Dacomitinib for locally advanced or metastatic EGFR positive non-small cell lung cancer – first line
2015	Health Council of the Netherlands Gezondheidsraad (GR)	Adriamycine. Health-based calculated occupational cancer risk values
2015	HAYES, Inc.	Endoscopic therapy for gastroesophageal reflux disease
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Fulvestrant (Faslodex) for advanced or metastatic, hormone-receptor positive breast cancer – first line
2015	Health Council of the Netherlands Gezondheidsraad (GR)	Neonatal screening: new recommendations
2015	HAYES, Inc.	Intensity modulated radiation therapy (IMRT) for anal or rectal cancer
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Idelalisib (Zydelig) with bendamustine and rituximab for chronic lymphocytic leukaemia – first line
2015	Health Council of the Netherlands Gezondheidsraad (GR)	Population Screening Act: study of faecal tests within the population based screening programme for colorectal cancer
2015	Health Quality Ontario (HQO)	Positional Magnetic Resonance Imaging for people with Ehlers-Danlos Syndrome or suspected craniovertebral or cervical spine abnormalities: an evidence-based analysis
2015	HAYES, Inc.	Lumbar total disc replacement for degenerative disc disease
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Nivolumab (Opdivo) for diffuse large B cell lymphoma –second line
2015	NIHR Public Health Research (PHR) programme	How effective are interventions at reducing socioeconomic inequalities in obesity among children and adults? Two systematic reviews
2015	Health Council of the Netherlands Gezondheidsraad (GR)	Antibiotics in hospitals: prophylaxis and antibiotic stewardship
2015	Health Quality Ontario (HQO)	Positional magnetic resonance imaging for people with Ehlers-Danlos syndrome or suspected craniovertebral or cervical spine abnormalities: OHTAC recommendation
2015	HAYES, Inc.	PCSK9 inhibitors for cholesterol reduction: evolocumab
2015	Canadian Agency for Drugs and Technologies in Health (CADTH)	Transoral robotic surgery: a review of clinical and cost-effectiveness
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Nivolumab for recurrent glioblastoma – second line
2015	Agency for Healthcare Research and Quality (AHRQ)	Cognitive outcomes after cardiovascular procedures in older adults: a systematic review
2015	Health Council of the Netherlands Gezondheidsraad (GR)	Chlorpromazine - Evaluation of the effects on reproduction, recommendation for classification
2015	Institute of Health Economics (IHE)	Rheumatoid arthritis in a policy perspective: a registry for research and better treatment of Albertans
2015	HAYES, Inc.	Percutaneous left appendage closure to reduce stroke risk in patients with atrial fibrillation
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Nivolumab (Opdivo) for Hodgkin lymphoma in brentuximab treated patients – second line